Filing Details

Accession Number:
0001415889-24-010777
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-04-12 18:23:49
Reporting Period:
2024-04-10
Accepted Time:
2024-04-12 18:23:49
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1672619 Enliven Therapeutics Inc. ELVN Pharmaceutical Preparations (2834) 811523849
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1805097 D. Rahul Ballal C/O Enliven Therapeutics, Inc.
6200 Lookout Road
Boulder CO 80301
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-04-10 13,600 $12.60 35,941 No 4 M Direct
Common Stock Disposition 2024-04-10 13,600 $21.01 22,341 No 4 S Direct
Common Stock Acquisiton 2024-04-11 48,820 $12.60 71,161 No 4 M Direct
Common Stock Acquisiton 2024-04-11 4,580 $19.68 75,741 No 4 M Direct
Common Stock Disposition 2024-04-11 30,300 $23.14 45,441 No 4 S Direct
Common Stock Disposition 2024-04-11 20,032 $25.00 25,409 No 4 S Direct
Common Stock Disposition 2024-04-11 3,068 $25.21 22,341 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2024-04-10 13,600 $0.00 13,600 $12.60
Common Stock Stock Option (right to buy) Disposition 2024-04-11 48,820 $0.00 48,820 $12.60
Common Stock Stock Option (right to buy) Disposition 2024-04-11 4,580 $0.00 4,580 $19.68
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
48,820 2028-10-19 No 4 M Direct
0 2028-10-19 No 4 M Direct
75,742 2029-05-16 No 4 M Direct
Footnotes
  1. The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.
  2. This transaction was executed in multiple trades at prices ranging from $21.00 to $21.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  3. This transaction was executed in multiple trades at prices ranging from $23.00 to $23.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  4. This transaction was executed in multiple trades at prices ranging from $24.015 to $25.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  5. This transaction was executed in multiple trades at prices ranging from $25.02 to $25.485. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  6. All of the shares subject to this option are fully vested and exercisable as of the date hereof.